Fundraising Fox
/Companies
Sign in

Akoya Biosciences

Acquired

Billerica, US · Founded 2015 · 2 known investors

Find your way into Akoya Biosciences

Sign up to find every way you can get introduced to Akoya Biosciences

  • Your email: who you already know at Akoya Biosciences, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Akoya Biosciences team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Quanterix (operating together with Akoya) develops biomarker measurement platforms that combine ultrasensitive blood/CSF liquid immunoassays with spatial tissue proteomics for research and clinical use in neurology, oncology, inflammation, cardiology and infectious disease. It serves pharmaceutical companies, CROs, diagnostics labs and academic researchers, offering CLIA-ready assays and spatial biology panels.

BiotechDigital HealthMedical Devices

Founders & leadership

BM
Brian McKelligonExecutive
GN
Garry NolanNamed on SEC filing
MW
Matthew WinklerNamed on SEC filing

Board

RHRob Hart
Rob HartBoard directorPartner at Telegraph Hill Partners
RSRobert Shepler
Robert SheplerBoard directorPartner Emeritus at Telegraph Hill Partners
TRThomas Raffin
Thomas RaffinBoard directorPartner Emeritus, M.D. at Telegraph Hill Partners

Investors · 2

Telegraph Hill Partnerslisted by Telegraph Hill PartnersSan Francisco · $2M – $8M

How we know: Telegraph Hill Partners's portfolio page · board seat on SEC Form D · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$33.5M disclosed across 2 rounds · 2017–2018

▶$24.5MraisedOct 2018 · 6 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Garry NolanDirector
  • Thomas RaffinDirector
  • Matthew WinklerDirector
  • Brian McKelligonExecutive Officer, Director
  • Robert SheplerDirector
  • Rob HartExecutive Officer
Offering amount
$25.5M
Amount sold
$24.5M
First sale
Sep 2018
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$9MraisedJul 2017 · 6 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Garry NolanDirector
  • Rob HartExecutive Officer
  • Robert SheplerDirector
  • Thomas RaffinDirector
  • Matthew WinklerDirector
  • Brian McKelligonExecutive Officer
Offering amount
$9M
Amount sold
$9M
First sale
Jul 2017
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 2

QuanterixQuanterix develops technology for highly sensitive detection of protein biomarkers using non-invasive sample types, aimed at early disease detection and prevention. The company serves the precision healthcare and life sciences research market with biomarker detection tools.
LeincoLeinco Technologies manufactures antibodies and proteins, offering both large- and small-scale IVD antibody and protein production along with CDMO services for scientists in life sciences discovery, biopharmaceutical, and diagnostics segments. Its reagents support research in areas such as cancer, infectious diseases, and immunology.

Companies working in the same space as Akoya Biosciences.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2018$149.6K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Akoya Biosciences do?
Quanterix (operating together with Akoya) develops biomarker measurement platforms that combine ultrasensitive blood/CSF liquid immunoassays with spatial tissue proteomics for research and clinical use in neurology, oncology, inflammation, cardiology and infectious disease. It serves pharmaceutical companies, CROs, diagnostics labs and academic researchers, offering CLIA-ready assays and spatial biology panels.
Who are Akoya Biosciences's investors?
Akoya Biosciences's investors include aMoon, Telegraph Hill Partners.
How much funding has Akoya Biosciences raised?
Akoya Biosciences has disclosed $33.5M raised across 2 rounds.
Where is Akoya Biosciences headquartered?
Akoya Biosciences is headquartered in Billerica, US.